280E relief is coming. Companies are leaner. Margins are about to expand big.
No specific external URLs were cited in this article. Analysis reflects the author’s interpretation of publicly available cannabis industry data, company financial filings, regulatory announcements, and market information current as of March 2, 2026. Individual data access dates were not recorded.
2025 was defined by waiting. Companies consolidated, cut costs, streamlined operations. Now 2026 is different. The President issued a direct order to cut regulatory red tape. And cannabis is in the crosshairs—in a good way.
Sheeba’s Analysis
IRS Section 280E is being targeted for elimination. Right now, cannabis companies can only deduct Cost of Goods Sold. Everything else—marketing, admin, distribution, R&D—is non-deductible. It’s a massive drag on profitability. When 280E goes away (and all signs point to Q1-Q2 2026), operating margins improve dramatically across the board.
The Math: For a company with $100M in revenue and $30M in non-COGS expenses currently locked out, that’s $9M+ in additional annual profit if you assume a 30% tax rate. Multiply that by GTI, Trulieve, and Curaleaf’s scales, and you’re looking at hundreds of millions in new shareholder value.
The landscape for 2026 has fundamentally shifted. Companies are leaner. Cost structures are improved. And now, the regulatory environment is moving for them instead of against them. That’s a rare triple play for cannabis operators. Watch TCNNF, GTBIF, and CURLF—margin expansion is incoming.